Semperit (SEM) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
13 Aug, 2026Executive summary
Revenue grew 11.1% year-over-year to EUR 355.9 million in H1 2026, with EBITDA more than doubling to EUR 66.6 million and a robust EBITDA margin of 18.7%.
Profitability improved significantly, with earnings after tax reaching EUR 28.6 million versus a loss of EUR 11.2 million in H1 2025; EPS was EUR 1.39.
Growth was driven by higher sales volumes, improved production utilization, and sustained cost and efficiency measures, despite increased raw material costs and market volatility.
Both Industrial and Engineered Applications divisions contributed to growth, with strong order intake, volume trends, and optimized capacity utilization.
Raised full-year EBITDA guidance to approximately EUR 100 million, reflecting confidence in continued operational strength.
Financial highlights
Revenue increased by 11.1% year-over-year to EUR 355.9 million in H1 2026.
EBITDA more than doubled to EUR 66.6 million, with EBITDA margin rising from 9.6% to 18.7%.
EBIT reached EUR 41.7 million, and earnings after tax improved to EUR 28.6 million from a loss of EUR 11.2 million in H1 2025.
Free cash flow more than doubled to EUR 30.4 million, supported by disciplined CapEx management.
Net financial debt decreased to EUR 79.9 million, and the equity ratio improved to 49.5%.
Outlook and guidance
Operating EBITDA for FY 2026 expected to reach approximately EUR 100 million.
Revenue growth anticipated in the high single-digit percentage range for the full year.
CapEx for 2026 forecast at EUR 40–45 million, with some project shifts rather than cuts.
Second half expected to be more challenging due to delayed impact of higher raw material costs and ongoing market volatility.
Margin protection remains a key focus through pricing discipline and efficiency measures.
Latest events from Semperit
- Q1 2026 saw strong revenue and EBITDA growth, but geopolitical and raw material risks remain.SEM
Q1 2026 - Margin recovery, innovation, and sustainability drive a strong 2026 growth outlook.SEM
Austrian Select Conference - Operating EBITDA beat guidance and margin rebounded; 2026 targets growth and higher profitability.SEM
Q4 2025 - Q3 2025 saw a strong EBITDA rebound and positive earnings, supporting a robust full-year outlook.SEM
Q3 2025 - Q2 recovery lifted order intake and margins; full-year EBITDA guidance and CapEx confirmed.SEM
Q2 2025 - EBITDA up 11.9% to EUR 63.9m, profit positive, and 2024 guidance reaffirmed.SEM
Q3 2024 - EBITDA up 7.9% to €47.3m, medical business divested, and cost savings exceeded targets.SEM
Q2 2024 - Q1 2025 saw steep profit declines, improved cash flow, and cautious optimism for H2 recovery.SEM
Q1 2025 - EBITDA up 21%, earnings positive, and free cash flow nearly doubled despite weak demand.SEM
Q4 2024